Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update
10. November 2021 07:30 ET
|
Wave Life Sciences USA, Inc.
Strengthened balance sheet with approximately $52 million; focusing additional investment in RNA editing programs led by hepatic editing Optimized AIMers for AATD program demonstrate potent, highly...
Wave Life Sciences to Present at the Stifel 2021 Virtual Healthcare Conference
08. November 2021 16:05 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021
01. November 2021 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences and Takeda Amend CNS Collaboration
18. Oktober 2021 17:00 ET
|
Wave Life Sciences USA, Inc.
Amendment to ongoing collaboration allows Wave to advance or partner CNS programs, including those using ADAR editing Takeda option to co-develop and co-commercialize late-stage CNS programs,...
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a Clinical Trial of WVE-N531 in Duchenne Muscular Dystrophy
29. September 2021 08:30 ET
|
Wave Life Sciences USA, Inc.
Trial is expected to enroll 15 boys with DMD amenable to exon 53 skipping First systemically administered therapeutic candidate with PN backbone chemistry modifications to be assessed in the clinic ...
Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast
28. September 2021 16:05 ET
|
Wave Life Sciences USA, Inc.
Durable ADAR editing in vivo in preclinical models, including in CNS tissues with editing out to at least four months Chemistry optimization yields a four-fold increase over PBS control in AAT...
Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference
22. September 2021 16:05 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease
09. September 2021 08:30 ET
|
Wave Life Sciences USA, Inc.
Only clinical-stage candidate for Huntington’s disease designed to selectively lower mutant HTT and spare wild-type HTT Adaptive trial design to enable faster optimization of dosing and...
Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor Research Webcast on September 28, 2021
08. September 2021 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07. September 2021 16:05 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...